Diadenosine polyphosphates (APnA) are endogenous dinucleoside molecules consisting of two adenosine moieties linked via their 59-ribose positions by a variable number of phosphate groups. APnA have been shown to be present in different cell types and to be released from platelets as well as co-released with catecholamines and ATP from bovine adrenal medulla. Candidate metabolites of APnA are ATP, ADP, AMP and adenosine. Vascular effects induced by APnA and their metabolites in several models have been reported to be mediated by A -and A -adenosine receptors as well as P2-purinoceptors. APnA have been demonstrated to differentially affect regional 1 2 perfusion, to influence cardiac output and blood pressure as well as the reactivity of isolated blood vessels and vascular beds. Vascular effects of APnA vary with the number of phosphate groups linking the adenosine molecules. This review outlines the effects of APnA on mesenteric and renal circulation. The effects of the antagonists varying with the type of vascular bed and the heterogeneous and dynamic vascular effects of diadenosine polyphosphates indicate a regionally different distribution of P2X and of P2Y purinoceptors in resistance arteries from different vascular beds. Although APnA have vasoconstrictor effects on the local level, it was repeatedly confirmed that systemically applied APnA induce hypotensive effects. The vasoconstrictor effects of APnA in isolated vessels are most prominent under resting tone conditions. In vivo, the vasculature exhibits a vasotone which makes dilatory effects more likely. Information on effects of APnA in vivo is still limited despite the fact that these compounds already have been used in man. 
. Introduction-properties of APnA
released during platelet activation [7] as well as co-released with catecholamines and ATP from bovine adrenal Diadenosine polyphosphates (APnA, n52-7) are molemedulla [8] . The dinucleotides are metabolized by soluble cules found ubiquitously in prokaryotes and eukaryotes.
enzymes in the blood plasma as well as by membraneThey are derived from ATP and consist of two adenosine bound ectoenzymes of endothelial cells, smooth muscle molecules bridged by two up to seven phosphate groups.
cells, and other cell types. In blood, APnA have a Diadenosine tetraphosphate (AP4A) was first identified in a considerably higher stability than ATP, which is cleaved chemical synthesis of ATP [1] and first shown to be into adenosine and phosphate within seconds [9, 10] . The biologically synthesized during protein synthesis [2] . All presence of the always co-released mononucleotides remammalian cells contain cytoplasmatic AP4A [3] . Dense tards the degradation of APnA [9] . The enzymatic cleavage granules of platelets have been shown to store AP3A [4] , of the dinucleotides plays a dual role for their biological AP4A [5] , AP5A and AP6A [6] . Diadenosine polyphosfunction: termination of the signal and generation of phates are metabolically inactive but are exocytotically purinergically active products such as ATP, ADP, AMP and finally adenosine [11] . The much higher potency of the dinucleotides compared with their metabolites in different 56 (2002) [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] models [12, 13] indicates that the effects evoked by APnA been considered as vasoconstrictors via smooth muscle are elicited by these dinucleotides themselves but not by ionotropic P2X1-like receptors [12, 17] . However, APnA their breakdown products. Local concentrations in the (n54-6) can additionally mediate vasorelaxation: promicroenvironment of a platelet thrombus adherent to a longed vasorelaxation following vasoconstriction and rapid damaged vessel might be 100 mM or higher initially [14] vasorelaxation after blockade of P2X1 receptor-mediated while in the circulating blood of an adult following platelet vasoconstriction [18, [28] [29] [30] . The effects of APnA on stimulation concentrations have been estimated to be of the vasotone depend on the experimental conditions and may order of 1 mM [5] . Physiologically, nanomolar to mireflect tissue and species differences of receptor exprescromolar concentrations of APnA are relevant for their sion. Furthermore, the current studies on APnA are based vascular effects [12] . AP2A derived from releasable on information derived from application of pharmacogranules of human platelets may play a regulatory role in logical tools of limited specificity. vascular smooth muscle growth as growth-promoting
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Recently the first use of APnA in anesthetized humans mediators [15] . The increased amount of dinucleoside was described where AP4A caused a sustained drop in polyphosphates in platelets from hemodialysis patients has blood pressure [31] . This illustrates the growing pharmacobeen regarded as an important additional atherogenic factor logical relevance of naturally occurring purinergic agents in renal replacement therapy [16] . The function of related such as APnA and the need of a better understanding of dinucleoside polyphosphates with guanosine moieties their pharmacological effects in vivo. The aim of this (APnG and GPnG) has been described recently [17, 18] .
review is to outline the effects of diadenosine polyphosphates on the small branches of the mesenteric vascular bed as well as renal resistance vessels.
. Signalling mechanisms
Since the functions of APnA have been studied in a range of models by multiple tools, the tables have been Vascular effects induced by APnA and their metabolites designed to systematize the occasionally divergent inin several models have been reported to be mediated by formation. Table 1 shows the agonists and antagonists used A -and A -adenosine receptors as well as P2-purinocepfor the study of vascular mesenteric and renal effects of 1 2 tors. P2X receptors on vascular smooth muscle cells APnA. It is obvious, that certain references are contradicmediate vasoconstriction. These receptors are coupled to tory regarding the selectivity of the agents. Table 2 reveals receptor-operated ion channels. The affinity to P2X that, in different models, APnA evoke divergent effects. purinoceptors of APnA has been shown in binding assays Tables 3 and 4 disclose that, for both, constrictor and [19] [20] [21] . P2Y-receptors are found on vascular smooth dilator effects of the purinergic agonists, dissimilar orders muscle and endothelial cells. Mainly, they are coupled to of potency were found depending on the model utilized. G-proteins [22] . Endothelium-induced, P2Y-mediated vasodilation may be converted to constriction after removal of the endothelium [12] . The vasodilator effects are 4 . Role of diadenosine polyphosphates in anesthetized thought to be induced via mechanisms which involve rats release of nitric oxide (NO) or prostacyclin (PGI2) [23] . 21 1
APnA activate predominantly a Ca -dependent K -conIn anaesthetized rats, i.v. infusion of APnA and their ductance in smooth muscle cells obtained from porcine degradation products induced a sustained drop of mean aorta most likely mediated via P2Y-purinoceptors and arterial blood pressure, that was fully reversible [32] . The possibly partially also by AP4A receptors [24] . A specific rank order of potency (Table 4) suggested that the diadenosine polyphosphate receptor has been identified on hypotensive effect is predominantly evoked by the original isolated cardiac myocytes [25] .
dinucleotides and not by their degradation products. Although vasoconstrictor effects of APnA have been demonstrated on the local level it was shown that sys-3 . Function temically applied APnA induce hypotensive effects. AP4A has been the most potent APnA to reduce mean arterial After Flores et al. published a comprehensive review on blood pressure in anesthetized rats after i.v. bolus injection the cardiovascular effects of APnA in 1999 [26] , data on [33] . There is no significant difference between the maximesenteric and renal vascular effects of APnA have been mal reductions of mean arterial blood pressure after i.v. published in abundance. Potency and type of response of infusion of AP4A [32] compared with the i.a. infusion or APnA is largely determined by the number of phosphates bolus injection or i.v. bolus injection reported previously (n) in the polyphosphate chain [12, 17, 18, 27, 28] (Tables 3  [33] . This indicates that there are most likely no significant and 4). APnA with a phosphate chain length of 2 up to 3 secondary effects due to either metabolism or compartphosphate groups have been regarded as vasodilators (via mentalization of AP4A. In experiments with i.v. infusion endothelial P2Y1-like receptors), while APnA with a of purinergic agonists, all (with the exception of a,bphosphate chain length of 4 up to 6 phosphate groups have mATP, see Table 1 for definition) reduced mean arterial [28, 32, 46] There are discrepancies in the literature concerning the selectivity of PPADS and ADP3959. Whereas in early studies on PPADS [12, 63, 64] and ADP3959 [61, 62] selectivity was assumed, recently data have been accumulated indicating lack of selectivity. blood pressure [32] . With the onset of mean arterial blood In anaesthetized rats [32] the AP5A-induced hypotenpressure decrease, a short transient reduction of heart rate sion was inhibited by the A antagonist DPCPX. An 1 was regularly observed. However, throughout the followapparent inhibition of relaxation of vascular smooth musing hypotensive period, the initial heart rate was restored.
cle by DPCPX via blockade of the A receptor is certainly 1 The P2X receptor antagonism of PPADS was the reason surprising. Only vasoconstriction has been found following for the inhibition of the hypertensive effect of a,b-mATP A receptor activation. Thus, either DPCPX blocked A 1 2 observed in anaesthetized rats [32] . The dose-response receptors as well, although at nanomolar concentrations it curves suggested a noncompetitive antagonism by PPADS.
is assumed to be specific for A receptors, or alternatively 1 The PPADS-triggered antagonism of the hypotensive effect and more likely, these effects were mediated via the known of AP5A at concentrations 10 times lower than those negative inotropic and chronotropic effects of activation of necessary for the inhibition of a,b-mATP was probably cardiac A receptors by APnA, resulting in hypotension 1 not due to P2X receptor antagonism because purinergic being antagonized by DPCPX. relaxation of vascular smooth muscle is known to be DMPX antagonized AP5A-induced hypotension at about mainly P2Y receptor-dependent. P2Y receptor antago-10 times higher concentrations than DPCPX [32] . In PPADS inhibited the effects of AP5A and, at higher [27] , this suggests an A antagonistic effect of DMPX on 2 concentrations, partially inhibited the effects of ATP and the vascular level. The pattern of antagonism of purinergic adenosine, but not of ADP and AMP [32] , further indicates effects of AP5A and its potential degradation products that the observed decrease in blood pressure is predomiobserved with DPCPX and DMPX supports the conclusion nantly caused by AP5A and not by its degradation that AP5A most likely acts as such because only at much products. The main limitation for a conclusive interpretahigher doses these antagonists partially decrease the effects tion is that PPADS, as most purinoceptor antagonists, is of ATP, ADP, or adenosine (DPCPX) or of ATP and not specific for single subtypes of these receptors and also adenosine (DMPX) but not of the other monoadenosine that the agonists have different affinities to the various phosphates. receptor subtypes. Furthermore, a possible influence of PPADS via inhibition of ectonucleotidases cannot be excluded. It could decrease breakdown of AP5A and thus 5 . Role of AP5A in the human forearm vascular bed would diminish the generation of degradation products. There are, however, no data demonstrating an inhibition of In volunteers, the forearm vasodilator response to intrab-AP5A breakdown via this mechanism.
rachially infused AP5A was augmented by dipyridamole, '1' is to signify that the authors of the original studies assume involvement of further receptors. The opposing effects of single agonists are, in part, explained by the experimental conditions, the basal tone of the vessels in which the compounds were studied, and may reflect tissue and species differences of receptor expression. an inhibitor of equilibrative nucleoside transport. The ,500 mm) and arterioles are most relevant [37, 38] . Busse adenosine receptor antagonist theophylline inhibited the et al. [30] investigated vasoactive properties of AP3A and vasodilator response to AP5A [35] . The measured con-AP4A in isolated, saline-perfused segments of rabbit centration of AP5A in venous plasma collected from the mesenteric arteries precontracted with norepinephrine. infused arm during intra-arterial administration of AP5A Neither AP3A nor AP4A was degraded during passage supported degradation of most of the infused AP5A during through segments. In rabbit mesenteric arteries, both one transit time. Adenosine and AP5A were equipotent nucleotides act directly on endothelial (AP4A) and / or vasodilators. The authors concluded that AP5A-mediated smooth muscle receptors without need for hydrolosis to forearm vasodilation is at least in part mediated by its metabolites. The endothelium-dependent dilator effect of breakdown product adenosine.
AP4A, is probably mediated by endothelial P2Y-purinoceptors [30] .
. Effects of APnA on mesenteric vasculature .3. Isolated perfused rat mesenteric arterial bed

.1. Dissociated smooth muscle cells
In basal tone preparations of the isolated perfused rat mesenteric arterial bed, mono-and dinucleotides elicited In the rat mesenteric vascular bed both, P2X and P2Y
vasoconstrictions (Tables 1 and 3 ) [12] . AP4A, AP5A and receptors were reported to be operational [36] . P2X AP6A provoked vasoconstriction, but not vasodilatation, 1 receptor immunoreactivity was detected in the smooth via P2X-purinoceptors. In contrast, the dinucleotides muscle layer of mesenteric artery rings [17] . The contribu-NADP, FAD, AP1A, AP2A and AP3A elicited vasodilattion of APnA metabolites in vivo differs from the situation ation, but not vasoconstriction, via endothelial P2Y-in ex vivo or in vivo studies due to ectonucleotidase purinoceptors. The authors suggested that molecules with activity on endothelium and blood cells in vivo as well as four or more phosphates are vasoconstrictors, while those due to dilution of ectonucleotidases in an organ bath. The with three or less phosphates are vasodilators [12] . sensitivity to a,b-mATP and desensitizing nature of rat mesenteric artery P2X receptors correspond closely to 6 .4. Isolated rat mesenteric resistance arteries and those of recombinant P2X receptors. Lewis et al. [17] superior epigastric arteries 1 determined the effects of APnA at P2X receptors on rat mesenteric arteries using the patch clamp technique on Steinmetz et al. [13] studied the effects of APnA in acutely dissociated artery smooth muscle cells. AP4A, densely and sparsely innervated rat resistance arteries. Rat AP5A and AP6A evoked concentration-dependent P2X mesenteric resistance arteries were the densely innervated receptor-mediated inward currents (Table 3) which dearteries and superior epigastric arteries the sparsely innersensitized during the application of higher concentrations vated ones examined. Sympathetic nerves are candidate of the agonist. AP2A and AP7A were ineffective. Similar sources and sites of action of endogenous adenine nucleoresults were obtained in contraction studies except for tides and APnA and can influence the presence of post-AP7A which evoked a substantial contraction [17] .
junctional receptors for neurotransmitters [13] . were comparable in the two vessel types except for their blood flow, effects on small muscular arteries (diameter duration of action [13] . Responses were maintained for several minutes in the epigastric vessels and highly (Table 1 ) elicited mesenteric arterial relaxation after an transient in the mesenteric resistance arteries. This does initial further increase in tone. not seem to be due to regional differences in the degradation of the agonists or to endothelium-dependent relaxa-6 .4.4. Heterogenous distribution of purinoceptors tion. Nerve-related degradation, which may be the case for
In rat mesenteric resistance arteries, P2X purinoceptors candidate neurotransmitters, can be ruled out because were demonstrated by functional analysis [40] and ausympathectomy did not modify the time course of the toradiography [41] . Mimicry of the effects by a,b-mATP responses. Differences in time course were not only and blockade of APnA-induced constrictions by PPADS observed with APnA but also with the degradation-resis- (Table 1) as well as by prior exposure to a high contant a,b-mATP. It was suggested that a regionally selective centration of a,b-mATP strengthen the suggestion that secondary relaxing effect of APnA is responsible for the P2X purinoceptors mediate the contractile responses intransient nature of the constrictive responses in the mesenduced by APnA [13] . These P2X purinoceptors seem to be teric resistance arteries [13] . located on the resistance artery smooth muscle cells. P2X receptors are responsible for vasoconstriction induced by AP5A because the nonselective P2 receptor 6 .4.2. Constriction in rat superior epigastric arteries antagonist suramin and, more specifically, PPADS which and mesenteric resistance arteries was regarded as a more selective P2X antagonist (Table 1 ) Administration of APnA and adenine nucleotides except inhibited AP5A-induced constriction of mesenteric resistadenosine and AMP induced constriction in rat superior ance arteries and less potently in superior epigastric epigastric arteries and mesenteric resistance arteries [13] .
arteries [42] . The absence of an effect of suramin in The rank order of potency was the same for both vessels superior epigastric arteries indicates that probably different (Table 3 ). High concentrations of AP3A induced stronger P2X receptors are expressed in these two resistance maximal constrictions than the more potent substances arteries. The antagonism of AP5A vasoactivity by PPADS AP5A and AP6A. This observation may be due to rapid was, however, noncompetitive. The fact that the antagondesensitizing effects coming into play before the potential ism of the prototype P2X receptor agonist a,b-mATP with maximum of the purinergic contraction was achieved these two antagonists was similar to that of AP5A further because desensitizing effects of AP5A and AP6A are supports the assumption that P2X receptors, possibly considerably stronger than those of AP3A. In line with the different subtypes, are responsible for the AP5A-induced higher affinity of especially AP5A and AP6A for P2X vasoconstriction in superior epigastric arteries and mesenreceptors in ligand-binding studies [19] , the larger APnA teric resistance arteries. P1 receptors are not contributing were more potent contractile agonists than ATP [13] .
significantly to the vasoconstrictor potency of AP5A, because both, the A and A receptor antagonists, failed to 1 2 6 .4.3. Dilation in rat superior epigastric arteries and influence the contractile effects of AP5A (Table 1) .
mesenteric resistance arteries
Another P2 receptor agonist, UTP, induced stable vasIn the agonist-constricted rat mesenteric arterial bed, oconstriction both in superior epigastric arteries and relaxing effects of APnA were reported [12] . The order of mesenteric resistance arteries. These vascular responses potency ( Table 4 ) differed from that of the contractile remained completely unchanged after prior desensitization effect of the compounds under basal conditions. In isolated by a,b-mATP or AP5A [42] . This indicates that another mesenteric resistance arteries, preconstricted with P2 receptor subtype is contributing to the vasoconstriction. phenylephrine, dynamic responses consisting of constricThe AP5A-induced vasorelaxation of phenylephrine-pretion and relaxation were observed at identical agonist constricted mesenteric arteries was inhibited by the P2Y1 concentrations and comparable agonist potency orders for receptor antagonist ADP3959 (Table 1 ) and the vasorelaxathe constrictive effects at resting tone and the relaxing tion induced by the P2Y agonist, ADPbS (Table 1) , was 1 effects at raised tone [13] . This discrepancy between both also inhibited by ADP3959 [42] . This suggests that AP5A-studies may originate from the use of bolus injections in induced vasorelaxation of mesenteric resistance arteries is the first and stable agonist concentrations maintained caused by P2Y receptor activation. Vasodilation induced 1 during several minutes in the latter. Furthermore, the by P2Y receptor activation has been described for the rat diameter of the perfused vessels [12] may have been larger mesenteric arterial bed [12, 36] . That vasodilation seen with and thus, vessel geometry, receptor spectrum, and reactivi-AP5A in precontracted mesenteric resistance arteries, was ty may differ in the vessels studied in the different groups.
due to activation of P2Y receptors has been confirmed by It is unlikely that the relaxing responses would be methe competitive antagonism of vasorelaxation with suramin diated by metabolites generated by asymmetric cleavage of and by the selective P2Y purinoceptor antagonist 1 the compounds [39] since ATP, ADP, AMP, and adenosine ADP3959 [42] . were ineffective or considerably less potent relaxing agents Surprisingly, PPADS also mitigated the vasodilation than AP5A and AP6A [13] . Not only APnA but also the induced by AP5A in preconstricted vessels [42] . This degradation-resistant P2X purinoceptor agonist a,b-mATP indicates that the selectivity of this antagonist is not restricted to P2X receptors only. P2Y receptor antagonism [38, 47] . The data are summarized in the following para-1 of PPADS has been suggested earlier [34] . graphs. Adenosine and the selective A receptor agonist 2 CGS21680 (Table 1) did not induce any significant 6 .5.1. Vasoconstriction in human mesenteric resistance vasorelaxation in mesenteric resistance arteries [42] thus arteries excluding that adenosine, as a degradation product of APnA with three up to six phosphate groups induced a AP5A, is responsible for vasorelaxation in mesenteric transient vasoconstriction in human mesenteric resistance resistance arteries involving A purinoceptor activation.
arteries [46] as has been shown in mesenteric resistance 2 Interestingly, the A receptor antagonist DMPX (Table 1) arteries of Wistar-Kyoto rats [13] . The rank order of 2A inhibited the vasorelaxation by AP5A in mesenteric resistpotency of APnA in human vessels was comparable to rat ance arteries. Because this inhibition was non-competitive mesenteric resistance arteries and to the perfused rat and occurred only at high concentrations of DMPX, this mesenteric artery of Wistar rats [12] (Table 3) . might reflect a nonspecific effect of DMPX.
AP4A-and AP5A-induced vasoconstrictions were inIon channel blockers have been used to clarify the hibited by the P2X purinoceptor antagonist, PPADS [46] . mechanisms involved in vascular action of APnA. ActivaThis suggests that the activation of P2X receptors is tion of P2X purinoceptors might lead to an increase in the responsible for AP4A-and AP5A-induced vasoconstriction 21 1 activity of Ca -dependent K channels because it leads to in human mesenteric arteries which is compatible with data 21 an increase in intracellular Ca [43, 44] . Such infrom rat mesenteric resistance arteries [13] . . Thus, K channel activation could be the smooth muscle constriction. Their pharmacokinetic and reason for the AP5A-induced relaxation of mesenteric pharmacological qualities vary considerably [48] . Between resistance arteries and offers another explanation for the homologous purinoceptor subtypes of man and rat there differences in the responses of mesenteric resistance are significant differences. The human P2X receptor is 4 arteries and superior epigastric arteries to AP5A. The sensitive to antagonism by suramin and PPADS, while the 21 1 inhibitors of such Ca -dependent K channels, clot-P2X receptor of the rat is not [49] . However, the identical 4 rimazole or apamin, however, did not reduce AP5A-ineffects of APnA and the same pharmacological pattern of duced vasodilation [42] . Since inhibition of ATP-depenantagonism in human and rat mesenteric resistance arteries 1 dent K channels by glibenclamide was without effect, suggest similar mechanisms of the contractile effects of 1 activation of K channels by AP5A is not responsible for APnA in rat and man. AP5A-induced vasorelaxation. APnA-induced arterial con- 21 traction most likely involves Ca influx through receptor-6 .5.2. Vasorelaxation in human mesenteric resistance operated channels [40, 45] , but the smooth muscle mechaarteries nism that leads to relaxation remains to be established. In After a preceding arterial contraction, APnA [46] caused smooth muscle cells obtained from porcine aorta, AP5A-a response with a terminal profound and long lasting 21 induced hyperpolarizations were inhibited by Ba and vasorelaxation in human mesenteric resistance arteries. clotrimazole but not by glibenclamide [24] . It was conThis pattern of vascular response matches that found in cluded that, in this model, APnA activate predominantly a mesenteric resistance arteries of Wistar-Kyoto rats [42] . In 21 1 Ca -dependent K -conductance. It is noteworthy that in contrast to the results in preconstricted rat mesenteric mesenteric resistance arteries contractions induced by resistance arteries, there was no significant difference 1 depolarizing high K solution were not attenuated by between APnA concerning their vasorelaxing potency in APnA [13] . The dual effects of APnA in rat mesenteric the human vascular preparation. However, in the rat resistance arteries are in line with findings that these mesenteric resistance artery a clear rank order of potency 21 compounds stimulate Ca influx and blunt the effects of was observed (Table 4 ) [42] and in the perfused rat kidney 21 angiotensin II on intracellular Ca concentration in [27] only AP3A and AP2A had a hypotensive potency. isolated arterial smooth muscle cells [45] .
AP5A-induced vasorelaxation in rat mesenteric resistance arteries was inhibited by P2Y receptor blockade [13] .
.5. Role of diadenosine polyphosphates in isolated
In contrast, in human mesenteric resistance arteries only human mesenteric resistance arteries vasodilation induced by AP4A but not that by AP5A was concentration-dependently inhibited by the P2Y purinocepWhile a range of data on effects of APnA in animal tor antagonist ADP3959 [46] . Furthermore, preincubation vessels have accumulated, little is known about whether or with the P2X purinoceptor antagonist PPADS inhibited not these data may be extrapolated to man. By microvessel concentration-dependently the AP4A-induced vasorelaxamyography, Steinmetz et al. [46] , evaluated the effects tion in human mesenteric resistance arteries whereas the induced by APnA (n53-6) and potential degradation same concentrations of the antagonist did not inhibit the products in human resistance size arteries in which up to vasorelaxation induced by AP5A. Again a remarkable 50% of the precapillary drop of blood pressure occurs difference was found between rat and human vessel reactivity. Thus, in human mesenteric resistance arteries, that AP4A induces vasoconstriction via A1 and P2X AP4A-induced vasorelaxation seems to be P2Y purinocepreceptors and vasodilatation via a receptor which is not a tor-mediated. The inhibitory effect of PPADS may reflect P2Y receptor [50] . The vasoconstrictive effects of AP2A the limited P2X selectivity of PPADS. Apparently, in man and AP3A were mostly due to stimulation of A1-receptors, AP5A activates different purinoceptors leading to vasorelaas shown by the inhibitory effect of DPCPX [27] . In raised xation.
tone preparations AP2A and AP3A evoked vasodilatation, which was blocked by the A2 receptor blocker, DMPX.
.
Role of diadenosine polyphosphates in the isolated perfused rat kidney 7 .2. Role of diadenosine polyphosphates in rat intrarenal microvasculature segments 7 .1. Role of diadenosine polyphosphates in the isolatedp erfused rat kidney Gabriels et al. [28] evaluated the effects of APnA on intrarenal microvasculature by analyzing interlobular artery The isolated perfused rat kidney has been used as a as well as afferent and efferent arteriole diameters after model for the renal vasculature to study the effects of application of AP3A, AP5A to the split hydronephrotic rat APnA. Activation of the purinoceptors in rat renal vasculakidney. Adenosine was additionally used as a reference ture by diadenosine polyphosphates with two up to six substance. Topical application of APnA induced constricphosphate groups was studied by measuring their effects tion in renal microvessels of the split hydronephrotic rat on perfusion pressure [27, [50] [51] [52] . The vasoconstrictor kidney. Administration of AP5A was followed by a more response to AP5A was first judged to be completely due to intense and longer lasting constriction than admission of P2X purinoceptor activation and that to AP4A and AP6A
AP3A. In line with the higher affinity of especially AP5A to be P2X purinoceptor-mediated to a large extent [27] .
and AP6A for P2X-purinoceptors in ligand binding studies The vasoconstrictor response to AP6A was partially in- [19] AP5A was the more potent contractile agonist. sensitive to A1 and P2X purinoceptor blockers [27] .
In preglomerular vessels, AP5A caused a more intense Responses to AP6A and a,b-mATP (Table 1) were vasoconstriction than AP3A and adenosine. This contrasts blocked by the selective P2X -receptor antagonist NF023
with the finding of equal and overall less pronounced 1 (Table 1) , whereas AP4A and AP5A were partially constrictory potencies for the efferent arteriole of the three blocked by the selective P2X -receptor antagonist NF023
agonists [28] and suggests a more direct involvement of that ATP, a P2-agonist, constricts afferent but not efferent whereas the sustained vasoconstriction was observed with arterioles whereas adenosine constricts both vascular segconcentrations $1 nM. AP5A and AP6A seemed to act via ments. Of the major segments of the intrarenal microvasthe same receptors as a,b-mATP. The rank order of culature, the afferent arteriole is most responsive to ATP potency for transient vasconstriction differed from that for [54] which is in line with the finding, that after transient sustained vasoconstriction (Table 3) . Suramin and PPADS constriction due to agonist addition, the afferent arteriole antagonized both the transient and the sustained vasocondoes not dilate unless P2X-purinoceptors are blocked [28] . striction. The authors concluded that the transient but not
In the study of Gabriels et al. [28] repeated administrathe sustained vasoconstriction is mediated via the P2X -tion of APnA reproducibly constricted renal vessels. Thus 1 receptor in rat renal vasculature [51] . After inhibition with receptor desensitization did not occur which also excludes PPADS, the remaining vasoconstriction of AP4A was that desensitization is responsible for the transient characblocked by the selective A1 receptor antagonist DPCPX ter of the effects. Inscho [55] stated that microvascular [50] . Inhibition of endothelial NO-synthase by L-NAME responses to adenosine include vasoconstriction at low did not affect vasoconstrictions induced by APnA [52] . By doses and vasodilation at higher concentrations. The comparison with dinucleoside polyphosphates with one or vasoconstriction is elicited in both pre-and postglomerular two guanosine moieties, van der Giet et al. [52] conclude arterioles. Inscho et al. [54] reported arcuate and interlobuthat P2X-receptors can only be activated if at least one lar arteries to exhibit transient vasoconstrictions with ATP adenosine moiety is present in the molecule and two while, in contrast, it evoked a sustained reduction in adenosine moieties enhance P2X-receptor binding and afferent arteriolar diameter with the efferent arterioles activation.
remaining unchanged. The fact that AP3A and AP5A, in In a raised tone preparation, AP4A evoked vasodilation contrast to ATP, elicit transient effects also in the afferent when P2 receptors were blocked by suramin [27, 50] . The arteriole indicates that these agonists probably provoke dilation was not mediated by a P2Y receptor as the effect purinoceptor-mediated vasodilation. This is further supwas not blocked by suramin. Thus, the authors concluded ported by the finding that, after inhibition of A -adenosine or P2X-receptors, the afferent arteriole dilated after addiInstead, the vasoconstriction induced by AP5A was antion of these agonists.
tagonized most effectively by the P2-receptor antagonist. Comparing the constrictor and dilator potencies of In the hydronephrotic rat kidney, the effects of AP5A, in adenosine and the APnA in the study of Gabriels et al. comparison to adenosine and AP3A, were less sensitive to [28] , it is evident that metabolism of APnA to adenosine the A -antagonist DPCPX but more sensitive to the P2-1 does not account for the observed effects. In that system, antagonists, PPADS and ADP3959, indicating that the intrarenal vessel diameters were augmented similarly by vasoconstriction is mediated by A -receptors and P2-1 adenosine, AP5A and AP3A 5 min after addition of the purinoceptors [28] . The lack of efferent P2X-receptor agonist. The interlobular artery and efferent arteriole were expression [60] clarifies the finding that PPADS does not dilated to a similar extent, while afferent arteriole diameter change the effect of adenosine, AP3A or AP5A in this was not augmented significantly. The latter finding may be segment [28] . the consequence of more intense vasoconstriction in this
In the hydronephrotic rat kidney, the vasodilation seen segment.
with adenosine, AP3A and AP5A was antagonized by the Intrarenally infused P2Y-agonists dilate renal vessels A -antagonist DMPX and by the P2-antagonist ADP3959 2 [56, 57] . It has been reported that by contacting the smooth [28] . The vasodilation emerging 5 min after addition of muscle from the adventitial side after superfusion, no adenosine, AP3A or AP5A was not altered by the A -1 significant afferent arteriolar vasodilation occurs [58] . antagonist, DPCPX, and by the P2-antagonist, PPADS Released from thrombocytes, APnA may gain access to [28] . While the pattern of late phase responses to the their receptors from the lumen. On the other hand endogantagonists was similar and clear in the interlobular artery enous purine nucleotides are released from sympathetic and the efferent arteriole, it was more complex in the nerve varicosities or in paracrine fashion from cells afferent arteriole. Vasodilation was only visible when the neighouring the renal microvasculature. Nucleotides re-A -receptors or the P2X-receptors were antagonized. This 1 leased from these sources will be delivered to the interstiindicates that, in the afferent arteriole, adenosine, AP3A tial fluid where they will interact with P2-receptors on and AP5A induce a more intense and longer lasting microvascular smooth muscle, mesangial cells, or tubular constriction which overrides the underlying dilation meand glomerular epithelium. In the study of Gabriels et al.
diated by activation of A -receptors or P2Y-purinoceptors 2 [28] , application of the substances to the bath most likely [28] . resulted in abluminal access of the APnA to the receptors activating the smooth muscle receptors first whereas, in the isolated perfused rat kidney, the compounds which are 8 . Summary administered to the luminal side meet the endothelial cells first. This and the absence of endothelial involvement in
In the mesenteric and renal vasculature, APnA directly the vasodilator response to APnA [30, 59] renders it less constrict rat vascular smooth muscle through P2X likely that the P2-agonists initiate the dilation by genepurinoceptors and subsequently trigger vascular relaxation ration of endothelium-dependent vasodilators although rat through related receptors or as a direct consequence of the renal purinoceptor-mediated vasodilation has been shown initial contractile mechanism. These effects and their to be converted to vasoconstriction by nitric oxide synthase regional heterogeneity do not involve the endothelium or inhibition with application of the agonist from the endoan acute or chronic sympathetic nervous influence. The thelial side [56, 57] , and removal of the endothelium of effects of the antagonists varying with the type of vascular intrarenal vessels converted vasodilation to constriction bed and the heterogeneous and dynamic vascular effects of [57]. However, Inscho et al. [58] concluded that in diadenosine polyphosphates indicate a regionally different superfused and blood perfused rat juxtamedullary afferent distribution of P2X and of P2Y purinoceptors in resistance nephrons, partial relaxation of ATP-constricted interlobular arteries from different vascular beds. arteries and afferent arterioles was not due to endogenous
The effect of at least AP5A is the result of vascular nitric oxide.
P2X, P2Y , A and A purinoceptor activation. These DPCPX, the A -receptor antagonist (Table 1) , completeeffects are fast in onset and easily reversible. The length of 1 ly abolished adenosine-induced vasoconstriction in the the phosphate chain of APnA determines the degree and hydronephrotic rat kidney [28] , whereas the A antagonist kind of vasomotor activity in rats. However, the vasodilat-2 DMPX and the P2-antagonists, PPADS and A3P5P, had no or potency of APnA does not change with the number of significant effects. In the isolated perfused rat kidney, the phosphate groups in human mesenteric resistance arteries. constriction by AP3A was mostly due to A -receptors, that
Although vasoconstrictor effects of APnA have been 1 by AP4A to A -and P2X-receptors and the constrictor demonstrated on the local level, it was repeatedly con-1 response to AP5A was due to P2X-purinoceptor activation firmed that systemically applied APnA induce hypotensivë [27, 50] . Similarly, Gabriels et al. [28] found complete effects. The vasoconstrictor effects of APnA in isolated inhibition of AP3A-induced vasoconstriction by the Avessels are most prominent under resting tone conditions. 
